Abstract
All the current sustained release formulation have a shortcoming of inability to maintain high blood levels for that long period with high disease intensity. This may lead to leaving the patient unprotected against the worse events of nocturnal asthma. Thus, a smart drug delivery that is administrated before sleep and maintains high blood levels for longer period (from midnight to 8 am in the morning, during which maximum intensity of the disease occurs) could be very much beneficial for proper management of nocturnal asthma. An attempt is undertaken to design and evaluate a chronomodulated drug delivery system of an antiasthmatic drug for the treatment of nocturnal asthma. A drug delivery system which is administered at bedtime, but releasing drug well after the time of administration (during morning hours) i.e., after a period of 6 h. These systems are beneficial for the drugs having chronopharmacological behavior where night time dosing is required and for the drugs having high first-pass effect, having specific site of absorption in gastrointestinal tract
